Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants

No Thumbnail Available
File version
Author(s)
Parsi, Kurosh
De Maeseneer, Marianne
van Rij, Andre M
Rogan, Christopher
Bonython, Wendy
Devereux, John A
Lekich, Christopher K
Amos, Michael
Bozkurt, Ahmet Kursat
Connor, David E
Davies, Alun H
Gianesini, Sergio
Gibson, Kathleen
Gloviczki, Peter
Grabs, Anthony
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2024
Size
File type(s)
Location
License
Abstract

BACKGROUND: Inadvertent intra-arterial injection of sclerosants is an uncommon adverse event of both ultrasound-guided and direct vision sclerotherapy. This complication can result in significant tissue or limb loss and significant long-term morbidity. OBJECTIVES: To provide recommendations for diagnosis and immediate management of an unintentional intra-arterial injection of sclerosing agents. METHODS: An international and multidisciplinary expert panel representing the endorsing societies and relevant specialities reviewed the published biomedical, scientific and legal literature and developed the consensus-based recommendations. RESULTS: Actual and suspected cases of an intra-arterial sclerosant injection should be immediately transferred to a facility with a vascular/interventional unit. Digital Subtraction Angiography (DSA) is the key investigation to confirm the diagnosis and help select the appropriate intra-arterial therapy for tissue ischaemia. Emergency endovascular intervention will be required to manage the risk of major limb ischaemia. This includes intra-arterial administration of vasodilators to reduce vasospasm, and anticoagulants and thrombolytic agents to mitigate thrombosis. Mechanical thrombectomy, other endovascular interventions and even open surgery may be required. Lumbar sympathetic block may be considered but has a high risk of bleeding. Systemic anti-inflammatory agents, anticoagulants, and platelet inhibitors and modifiers would complement the intra-arterial endovascular procedures. For risk of minor ischaemia, systemic oral anti-inflammatory agents, anticoagulants, vasodilators and antiplatelet treatments are recommended. CONCLUSION: Inadvertent intra-arterial injection is an adverse event of both ultrasound-guided and direct vision sclerotherapy. Medical practitioners performing sclerotherapy must ensure completion of a course of formal training (specialty or subspecialty training, or equivalent recognition) in the management of venous and lymphatic disorders (phlebology), and be personally proficient in the use of duplex ultrasound in vascular (both arterial and venous) applications, to diagnose and provide image guidance to venous procedure. Expertise in diagnosis and immediate management of an intra-arterial injection is essential for all practitioners performing sclerotherapy.

Journal Title

Phlebology: The Journal of Venous Disease

Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note

This publication has been entered in Griffith Research Online as an advance online version.

Access the data
Related item(s)
Subject
Persistent link to this record
Citation

Parsi, K; De Maeseneer, M; van Rij, AM; Rogan, C; Bonython, W; Devereux, JA; Lekich, CK; Amos, M; Bozkurt, AK; Connor, DE; Davies, AH; Gianesini, S; Gibson, K; Gloviczki, P; Grabs, A; Grillo, L; Hafner, F; Huber, D; Iafrati, M; Jackson, M; Jindal, R; Lim, A; Lurie, F; Marks, L; Raymond-Martimbeau, P; Paraskevas, P; Ramelet, A-A; Rial, R; Roberts, S; Simkin, C; Thibault, PK; Whiteley, MS, Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants, Phlebology: The Journal of Venous Disease, 2024

Collections